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Between June and September 2013, sera from 11 drom-
edary camels, 150 goats, 126 sheep and 91 cows were 
collected in Jordan, where the first human Middle-
East respiratory syndrome (MERS) cluster appeared 
in 2012. All sera were tested for MERS-coronavirus 
(MERS-CoV) specific antibodies by protein microarray 
with confirmation by virus neutralisation. Neutralising 
antibodies were found in all camel sera while sera 
from goats and cattle tested negative. Although six 
sheep sera reacted with MERS-CoV antigen, neutralis-
ing antibodies were not detected.
In the period between June and September 2013, sera 
from 11 dromedary camels, 150 goats, 126 sheep and 91 
cows were collected predominantly in the al Zarqa gov-
ernorate, Jordan, where the first human Middle-East 
respiratory syndrome (MERS) cluster appeared in April 
2012 [1]. All sera were tested for the presence of MERS-
coronavirus (MERS-CoV) specific antibodies by protein 
microarray with confirmation by virus neutralisation. 
Neutralising antibodies to MERS-CoV were found in all 
sera from dromedary camels while the sera from goats 
and cattle tested negative. Although six of 126 sheep 
sera reacted with the MERS-CoV antigen, neutralising 
antibodies were not detected. The reactivity of sheep 
sera from this region observed in the microarray war-
rants further study. 
Background
In 2012 MERS-CoV was identified in patients with 
severe respiratory disease in the Middle East. As of 
2 December 2013, a total of 163 laboratory-confirmed 
cases including 70 deaths have been reported to 
the World Health Organization (WHO) [2]. All cases 
reported to date were linked to Jordan, Kuwait, Oman, 
Qatar, Saudi Arabia (SA) or the United Arab Emirates 
(UAE). Human to human transmission has been 
observed in healthcare and family settings [3]. Various 
studies indicate that the observed MERS-CoV diversity 
in humans results from multiple independent introduc-
tions in the human population in the Middle East [5-7] 
and the number of these sporadic, primary infections 
is still increasing [2]. The animal reservoir(s) for MERS-
CoV are still unknown but serological studies demon-
strated that dromedary camels in the Canary Islands, 
Egypt and Oman have been infected with MERS-CoV 
or MERS-related-CoV [8,9]. Of these countries, human 
cases have only been detected in Oman [2]. 
Data provided by the Food and Agriculture Organization 
of the United Nations (FAO) from 2012 show that cows, 
dromedary camels, goats and sheep are the main 
sources of meat and milk in the affected countries 
[4]. In addition, in Saudi Arabia, where the majority of 
MERS cases have been reported, roughly one sheep is 
sacrificed for each pilgrim or one camel for seven pil-
grims in the Hajj (yearly Muslim pilgrimage to Mecca), 
which can amount up to the slaughter and worldwide 
distribution of meat of around three million Middle-
Eastern sheep and camels, based on the pilgrim num-
bers reported for 2011 and 2012 [10]. The continued 
occurrence of human MERS cases, the presence of neu-
tralising antibodies in camels and the extensive animal 
exposure (including animal products) of humans war-
rant extensive studies in livestock aimed at identifying 
the possible reservoir of MERS-CoV. 
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Figure 1
Animal sampling locations for the MERS-CoV serological study, relative to the location where MERS-CoV human cases 
were identified in April 2012, Jordan, June–September 2013
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MERS-CoV: Middle East Respiratory Syndrome coronavirus.
A represents Al-Zarqa, the city were the first human Middle-East respiratory syndrome cases were identified in April 2012. 
B-F are locations where animal sampling took place between June and September 2013.
Source: map adapted from: http://d-maps.com/carte.php?num_car=5402&lang=en
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In April 2012, an outbreak of acute respiratory illness 
occurred in an intensive care unit in a public hospital 
in Zarqa city, Zarqa governorate, Jordan. Retrospective 
testing identified MERS-CoV as the confirmed and 
probable causative agent of two and 11 patients respec-
tively. Ten people in the outbreak were healthcare 
workers (HCW). The two confirmed cases, a HCW and 
an admitted patient, died [1]. Although epidemiological 
investigations identified limited nosocomial transmis-
sion, the primary source for MERS-CoV transmission to 
humans was not identified. 
Middle East Respiratory Syndrome 
coronavirus serological study in livestock 
Between June and September 2013, sera as well as fae-
cal swabs from 11 dromedary camels, 150 goats, 126 
sheep and 91 cows were collected predominantly in the 
al Zarqa governorate, Jordan (Table 1, Figure 1). All sera 
were tested for the presence of IgG antibodies reactive 
with MERS-CoV, Severe Acute Respiratory Syndrome 
coronavirus (SARS-CoV), and human coronavirus OC43 
(HCoV-OC43) S1 antigens exactly as described before 
[9,11]. HCoV-OC43 is serologically closely related to 
bovine coronavirus (BCoV) and used as a proxy to 
detect antibodies against BCoVs that are commonly cir-
culating in ungulates [9]. 
All 11 dromedary camel sera and six of 126 sheep sera 
had antibodies against the MERS-CoV S1 antigen while 
there was no reactivity in goat and cow sera. Four of 
11 dromedary camels, 23/91 cows, 128/150 goats and 
all sheep reacted with HCoV-OC43 antigen. None of the 
sera bound to SARS-CoV antigen (Figure 2).  
For confirmation, all camel and sheep sera (n= 137) 
were tested in a MERS-CoV neutralisation assay, 
exactly as described before [9]. All camel sera had 
MERS-CoV neutralising antibodies with titres varying 
between 1:20 and 1:80, while no neutralising antibod-
ies were detected in the sheep sera (Table 2 and data 
not shown). As coronavirus serology is potentially 
complicated due to the general circulation of BCoVs in 
these four livestock species (cross-reactivity needs to 
be excluded), a comparative plaque reduction neutrali-
sation test (PRNT) for MERS-CoV and BCoV was per-
formed on all camels sera and a subset of goat, sheep 
and cow sera, exactly as described before [9] (Table 
2). All camel sera inhibited MERS-CoV plaque forma-
tion with titres varying between 1:40 and 1:80, while 
again no inhibition was observed with the selection of 
sheep sera.  Four of the 11 camel sera also inhibited 
BCoV plaque formation with titres between 1:160 and 
1:320, confirming the microarray results for these sam-
ples. BCoV neutralising titres varied between 1:40 and 
1:160 for the selection of sheep sera, between 1:40 and 
1:320 for the subset of goat sera and between 1:40 and 
1:>1,280 for the subset of bovine sera. 
Faecal samples of camels and sheep were analysed for 
identification of viral sequences using pancoronavirus 
and specific polymerase chain reaction (PCR) methods 
[9]. Three BCoV sequences but no MERS-CoV or MERS-
related CoV sequences were obtained from sheep rec-
tal swabs.
Discussion
Here, we describe a serological study in various live-
stock species (n= 378) of economic importance in a 
Table 1
Characteristics of animals included in the Middle East Respiratory Syndrome (MERS) coronavirus serological study, Jordan, 
June–September 2013 (n= 378 animals)
Animals (total numbers) Locationa,b Number Sex Age
Dromedary camels (n=11) Ec, outdoors 11 M 3–14 months
Sheep of Awassi breed (n=126) Ec, indoors 20 F > 2 years
C, outdoors 53 F + M All agesd
D, outdoors 27 F + M > 2 years
B, indoors 26 F + M All agesd
Cows (n=91) C, indoors 35 F Unknown
F, indoors 56 F Unknown
Goats of local breed (n=150) D, indoors 10 F + M Unknown
C, unknown 91 F + M Unknown
B, unknown 49 F + M Unknown
M: male; F: female.
a The letters B, C, D, E, and F refer to locations indicated in Figure 1.
b If known, it is indicated whether the animals were kept indoors or outdoors.
c The respective locations of the sheep and camels were 5 km apart and there was no contact between the sheep and camels. 
d Females were older than 2 years and males were younger than 6 months.
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Figure 2
Reactivity of livestock sera (n= 378) from Jordan with three coronavirus S1 antigens
Ag: antigen; MERS-CoV: Middle East Respiratory Syndrome coronavirus; hCoV-OC43: human coronavirus OC43; SARS-CoV: Severe Acute 
Respiratory Syndrome coronavirus.
Column scatterplot of relative fluorescent intensities per antigen (y-axis) measured by protein microarray for dromedary camel (n=11), goat 
(n=150), sheep (n=126) and cow (n=91) sera from Jordan at serum dilution 1:20. 
Black lines indicate medians. Dashed black line is cutoff of the assay for MERS-CoV. Dashed grey line is cutoff of the assay for HCoV-OC43.
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Table 2
Results of neutralising assays for Middle East Respiratory Syndrome coronavirus and bovine coronavirus, serological study in 
livestock, Jordan, June–September 2013
Number of serum 
samples
Positive MERS-CoV neutralisation titrea 
n (titres)
Positive BCoV neutralisation titreb 
n (titres)
Dromedary camels n= 11
MERS-CoV antigen array signal (RFU)
<10,000 0 0 (NS) 0 (NS)
10,000–20,000 0 0 (NS) 0 (NS)
20,000–30,000 0 0 (NS) 0 (NS)
30,000–40,000 2 2 (1:20 to 1:40) 0 (NS)
>40,000 9 9 (1:20 to 1:80) 4 (1:160 to 1:320)
hCoV-OC43 antigen array signal (RFU)
<10,000 9 9 (1:20 to 1:80) 2 (1:320)
10,000–20,000 2 2 (1:80) 2 (1:160)
20,000–30,000 0 0 (NS) 0 (NS)
30,000–40,000 0 0 (NS) 0 (NS)
>40,000 0 0 (NS) 0 (NS)
Sheep n= 10
MERS-CoV antigen array signal (RFU)
<10,000 4 0 (NS) 3 (1:80 to 1:160)
10,000–20,000 0 0 (NS) 0 (NS)
20,000–30,000 1 0 (NS) 1 (1:40)
30,000–40,000 2 0 (NS) 2 (1:40 to 1:160)
>40,000 3 0 (NS) 2 (1:40 to 1:80)
hCoV-OC43 antigen array signal (RFU)
<10,000 1 0 (NS) 0 (NS)
10,000–20,000 0 0 (NS) 0 (NS)
20,000–30,000 1 0 (NS) 0 (NS)
30,000–40,000 2 0 (NS) 2 (1:40)
>40,000 6 0 (NS) 6 (1:40 to 1:160)
Goat n= 8
MERS-CoV antigen array signal (RFU)
< 10,000 7 0 (NS) 3 (1:40 to 1:320)
10,000–20,000 1 0 (NS) 1 (1:160)
20,000–30,000 0 0 (NS) 0 (NS)
30,000– 40,000 0 0 (NS) 0 (NS)
>40,000 0 0 (NS) 0 (NS)
hCoV-OC43 antigen array signal (RFU)
<10,000 3 0 (NS) 0 (NS)
10,000–20,000 0 0 (NS) 0 (NS)
20,000–30,000 0 0 (NS) 0 (NS)
30,000–40,000 1 0 (NS) 0 (NS)
>40,000 4 0 (NS) 4 (1:40 to 1:320)
Bovine n= 7
MERS-CoV antigen array signal (RFU)
<10,000 7 0 (NS) 7 (1:80 to 1: >1,280)
10,000–20,000 0 0 (NS) 0 (NS)
20,000–30,000 0 0 (NS) 0 (NS)
30,000–40,000 0 0 (NS) 0 (NS)
>40,000 0 0 (NS) 0 (NS)
hCoV-OC43 antigen array signal (RFU)
<10,000 4 0 (NS) 4 (1:80 to 1:160)
10,000–20,000 3 0 (NS) 3 (1:160 tp 1: >1,280)
20,000–30,000 0 0 (NS) 0 (NS)
30,000–40,000 0 0 (NS) 0 (NS)
>40,000 0 0 (NS) 0 (NS)
BCoV:  bovine coronavirus; hCoV-OC43: human coronavirus OC43; MERS-CoV: Middle East Respiratory Syndrome virus; NS: not shown;  
PRNT: plaque reduction neutralisation test; RFU: relative fluorescence units.
a based on both microneutralisation with starting dilution 1:10 and PRNT with starting dilution 1:40. 
b based on PRNT with starting dilution 1:40. 
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region in Jordan where a cluster of human MERS cases 
occurred. 
No evidence for the presence of antibodies directed 
against MERS-CoV was found in 91 cattle and 150 goat 
sera. MERS-CoV neutralising antibodies were found 
in all 11 dromedary camel sera. Circulation of BCoV in 
dromedary camels is known but cross-neutralisation 
between MERS-CoV (a lineage C beta-coronavirus) and 
BCoV (a lineage A beta-coronavirus) or other CoVs, 
including SARS-CoV (a lineage B betacoronavirus), has 
been conclusively excluded in previous studies and was 
illustrated again in this study in the comparative PRNTs 
[8,9]. These observations indicate that MERS-CoV or a 
highly related virus circulated in dromedary camels in 
a region where transmission to humans occurs. 
The neutralisation titres observed in the Jordan camel 
sera were lower than observed with sera from Oman 
but in the same range as those observed on the Canary 
Islands [9]. The dromedary camels in this study were 
calves, only three to 14 months of age, and these low 
titres might reflect the presence of waning maternal 
antibodies. However, maternal antibodies in drom-
edary camels reportedly decline rapidly two to five 
weeks after birth [12] and much higher antibody titres 
against MERS-CoV were observed in adult dromedary 
camels (older than four years of age) in the Middle-
East region and the Horn of Africa [8,9] (and data not 
shown). Therefore an alternative explanation could be 
that the camels had just been infected and antibody 
titres were still rising. 
Interestingly, six sheep sera reacted with MERS-CoV 
S1 antigen on the array while previous validation 
experiments using sheep sera from the Netherlands 
showed no reactivity [9]. This previous study included 
HCoV-OC43 S1-reactive and non-reactive sheep sera 
emphasising that there should not be any cross-reactiv-
ity between the MERS-CoV antigen and BCoV-specific 
antibodies due to BCoV circulation. However, none of 
the 126 sheep sera showed MERS-CoV neutralising 
activity. The applied sheep sera were highly haemo-
lytic which may have caused some assay interferences.
Our observation strengthens our earlier study in which 
MERS-CoV neutralising antibodies were found in drom-
edary camels in Oman where human cases have been 
reported as well [2]. Until the virus that elicits these 
antibodies in camels is detected, sequenced and com-
pared to the viruses sequenced from human patients, 
it remains unclear whether this livestock species is 
indeed infected with MERS-CoV and thus represents an 
immediate source for human infection. However, our 
observations should be used to focus virological and 
serological studies in livestock, especially dromedary 
camels and sheep, and including humans handling 
these animals and their products.
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